Regional treatment with liquid barrier agents: A novel therapeutic option for intraperitoneal endometriosis?
article
OA: closed
CC0
⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study investigates the efficacy and safety of regional treatment with liquid barrier agents as a potential therapeutic approach for intraperitoneal endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (32)
- Cellular Exchange in an Endometriosis-Adhesion Model Using GFP Transgenic Mice via openalex
- Clinical Presentation and Diagnosis of Endometriosis via openalex
- Elevated angiogenin levels in the peritoneal fluid of women with endometriosis correlate with the extent of the disorder via openalex
- Endometriosis and infertility via openalex
- Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications via openalex
- Endometriosis: in search of optimal treatment. via openalex
- Immunology of endometriosis via openalex
- Immunology of endometriosis. via openalex
- Increased levels of interleukin-15 in the peritoneal fluid of women with endometriosis: inverse correlation with stage and depth of invasion via openalex
- Patients' report on how endometriosis affects health, work, and daily life via openalex
- Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity via openalex
- Peritoneal endometriosis is an inflammatory disease via openalex
- Peritoneal endometriosis is an inflammatory disease via openalex
- Peritoneal fluid concentrations of interleukin-8 in patients with endometriosis depend on the severity of the disorder and are higher in the luteal phase via openalex
- Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation via openalex
- Reactive Oxygen Species Controls Endometriosis Progression via openalex
- Role of cytokines in the endometrial-peritoneal cross-talk and development of endometriosis via openalex
- The Epidemiology of Endometriosis via openalex
- Tumor necrosis factor-α but not interleukin-1β or interleukin-8 concentrations correlate with angiogenic activity of peritoneal fluid from patients with minimal to mild endometriosis via openalex
- W6713381459 via openalex
- W1985959551 via openalex
- W2020614791 via openalex
- W2079190330 via openalex
- W2107051613 via openalex
- W2115394515 via openalex
- W2126728673 via openalex
- W2130355009 via openalex
- W2132577372 via openalex
- W2141754511 via openalex
- W2144512243 via openalex
- W2160174091 via openalex
- W6604541379 via openalex
Cited by (3)
- A case of cyclic hemoperitoneum in a hemodialysis patient: Encapsulated peritoneal sclerosis complicated by endometriosis and fungal peritonitis 2020
- Inhibition of Adhesion, Proliferation, and Invasion of Primary Endometriosis and Endometrial Stromal and Ovarian Carcinoma Cells by a Nonhyaluronan Adhesion Barrier Gel 2015
- Treatment efficacy for pain complaints in women with endometriosis of the lesser pelvis after laparoscopic electroablation vs. CO2 laser ablation 2014
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:19:05.543671+00:00
License: CC0
· commercial use OK